Tenax Therapeutics Inc. (TENX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Tenax Therapeutics Inc.

    NASDAQ: TENX · Real-Time Price · USD
    6.81
    0.31 (4.77%)
    At close: Sep 25, 2025, 3:59 PM
    6.88
    1.03%
    After-hours: Sep 25, 2025, 07:01 PM EDT

    Tenax Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a 7.57K 113.33K 108.98K
    Gross Profit
    		 n/a -7.57K -113.33K -108.98K
    Operating Income
    		 -19.49M -8.23M -11.05M -32.73M
    Interest Income
    		 1.91M n/a 4.44 n/a
    Pretax Income
    		 -17.6M -7.71M -11.05M -32.47M
    Net Income
    		 -17.6M -7.71M -11.05M -32.47M
    Selling & General & Admin
    		 6.79M 5.01M 5.68M 7.58M
    Research & Development
    		 12.71M 3.23M 5.38M 25.15M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 19.49M 8.23M 11.05M 32.73M
    Interest Expense
    		 23K 23.97K 4.44K 949.00
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 -19.49M 8.23M 11.05M 32.73M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 15.27M 248K 18.39K 12.86K
    Shares Outstanding (Diluted)
    		 15.27M 248.45K 18.39K 12.86K
    EPS (Basic)
    		 -1.15 -31.09 -600.8 -2.52K
    EPS (Diluted)
    		 -1.15 -31.04 -600.8 -2.52K
    EBITDA
    		 -17.58M -7.68M -10.93M -32.36M
    EBIT
    		 -17.63M -7.69M -11.04M -32.47M
    Depreciation & Amortization
    		 46K 7.57K 113.33K 108.98K

    Add to Watchlist